Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 14, Issue 6, Pages 741-749Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2014.895326
Keywords
basal cell carcinoma; hedgehog; locally advanced; metastatic; vismodegib
Categories
Ask authors/readers for more resources
The hedgehog (Hh) signaling pathway has been identified as important to normal embryonic development in living organisms and it is implicated in processes including cell proliferation, differentiation and tissue patterning. Aberrant Hh pathway has been involved in the pathogenesis and chemotherapy resistance of different solid and hematologic malignancies. Basal cell carcinoma (BCC) and medulloblastoma are two well-recognized cancers with mutations in components of the Hh pathway. Vismodegib has recently approved as the first inhibitor of one of the components of the Hh pathway (smoothened). This review attempts to provide current data on the molecular pathways involved in the development of BCC and the therapeutic options available for the treatment of locally advanced and metastatic BCC, and the new targeted therapies in development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available